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Gait and balance measures have particular potential as outcome measures in Multiple Sclerosis (MS) because, of the many
hallmarks of MS disability, gait and balance dysfunction are present throughout the course of the disease, impact many aspects of a
person’s life, and progress over time. To highlight the importance and relevance of gait and balance measures in MS, explore novel
measurementsofgaitandbalanceinMS,anddiscusshowgait,balance,andfallmeasurescanbestbeusedanddevelopedinclinical
and research settings, the 1st International Symposium on Gait and Balance in Multiple Sclerosis was held in Portland, Oregon,
USA on October 1, 2011. This meeting brought together nearly 100 neurologists, physiatrists, physical therapists, occupational
therapists, nurses, engineers, and others to discuss the current status and recent advances in the measurement of gait and balance
in MS. Presentations focused on clinician-administered, self-administered, and instrumented measures of gait, balance, and falls
in MS.
1. Statement of Need
In the last 30 years, we have made great strides in the treat-
mentofMS.Wehavedevelopedandbroughttomarketseven
disease-modifying medications to reduce the frequency of
MS relapses and slow the accumulation of irreversible
disability, and many therapies are available to control MS-
related symptoms. However, none of these interventions
cures MS or halts its progression. One of the signiﬁcant chal-
lenges for developing new and better therapies for MS is that
current measures, including the neurological examination,
the Expanded Disability Status Scale (EDSS), the Multiple
SclerosisFunctionalComposite(MSFC),MRImeasures,and
relapse rates, have limited ability to capture between-relapse
and ongoing disease progression in the absence of relapses.
As Dennis Bourdette, M.D., Chairman of the Department of
Neurology at Oregon Health & Science University (OHSU)
said, “what we need [in MS] are measures that are quick,
easy, accurate, and sensitive to change—both worsening and
improvement—and are understandable [to clinicians]...gait
and balance measures have the potential to meet these re-
quirements.” He emphasized the need for communication
between neurologists and others caring for people with MS
and conducting clinical trials and nonneurologists engaged
in developing and testing measures of gait and balance.
2. Clinician-AdministeredMeasures
Clinician-administered measures of gait and balance are the
measures most commonly used in clinical practice. These
measures are generally inexpensive and easy to administer,
and many have been validated in people with MS. However,
as highlighted by Rebecca Spain, M.D., MSPH, a neurologist
from OHSU, because of the diverse goals and perspectives of
diﬀerent clinicians, one measure is not likely to meet every
clinician’s needs. Neurologists localize neuroanatomically
and seek guidance for recommending medications that glob-
ally eﬀect MS-related health. In contrast, physical therapists
and engineering-based researchers evaluate biomechanical
details that underlie gait and balance abnormalities and seek2 Multiple Sclerosis International
improved methods to direct targeted rehabilitation interven-
tions.
Francois Bethoux, M.D., a physiatrist from the Cleveland
Clinic, noted that many of the currently used clinician-
administered measures of gait, including the timed 25-foot
walk (T25FW) [1], the 6-minute and 2-minute walk tests
(2MWT [2], 6MWT [3]), and the Timed Up and Go (TUG)
test [4], can detect changes in gait speed or endurance [5]
but do not detect visually obvious improvements in gait
quality, or assess important contributors to gait changes such
as reduced cognitive function, visual function, upper body
trunk control, spasticity, or sensation. Although this limits
their utility for guiding selection of speciﬁc interventions,
thesesimpleclinician-administeredmeasuresarestillrecom-
mended for screening individuals for gait impairment and
for standardized assessment of performance over time.
Susan Bennett, PT, Ed D from the University of Buf-
falo, described some of the more sophisticated clinician-
administered measures of balance, such as the Berg Balance
Scale(BBS)[6],thefunctionalreachtest,[7]andtherecently
developed 4-square-step test [8] and mini-BEST test [9].
These measures can diﬀerentiate between people with MS
who fall from those who do not (BBS [10], 4-square-step test
[11]) and can provide information to guide rehabilitation.
Dr. Bennett also emphasized the utility of the trunk control
test [12, 13] for assessing balance in nonambulatory patients
for whom postural control of the trunk is essential for safe
and independent transfers.
3.Self-AdministeredMeasures
Marcia Finlayson, OT, Ph.D., from the University of Illinois
at Chicago, noted that self-reported measures, also known
as Patient Reported Outcome Measures (PROMs), have
recently attracted attention from government agencies, in-
cluding the National Institutes of Health and Food and Drug
Administration, because these measures capture directly
from patients how they feel or function without interpreta-
tion by others. This information from the patient’s perspec-
tive is important. Self-reported measures of gait and balance
can ascertain patients’ quality of life, balance conﬁdence, fear
of falling, circumstances surrounding fall events, and other
importantinformationthatcannotbedeterminedbyclinical
testing or physical instrumentation. These data are usually
best captured with diaries, questionnaires, surveys, or web-
based methods.
Joanne Wagner, PT, Ph.D., from Saint Louis University,
discussed the MS Walking Scale-12 (MSWS-12) [14], the
only PROM speciﬁc to walking in MS. This scale assesses
self-perceived limitations in walking due to MS. MSWS-
12 scores correlate with clinician-administered and instru-
mented measures of walking, including the EDSS (r = 0.65
to 0.84) [14, 15], the T25FW (r = 0.46 to 0.65) [14, 15],
the 6MWT (r = 0.81), [16] the metabolic cost of walking
(r = 0.64), [17] and free-living accelerometry (r =− 0.48
to −0.79) [17, 18]. The MSWS-12 also has high test-retest
reliability (ICC 0.75 to 0.87) [14, 19], was responsive to
change in two medication trials in MS, and has acceptable
ﬂoor and ceiling eﬀects. A second version of the MSWS-
12, adapted from the ﬁrst version based on Rasch analysis,
has been developed and submitted for publication (Hobart,
personal communication). Michelle Cameron, M.D., PT, a
neurologist from OHSU, discussed the Activities-Speciﬁc
Balance Conﬁdence (ABC) scale [20] and the Dizziness
Handicap Inventory (DHI), [21] the two self-administered
measures of balance measures frequently used in people with
MS which, although originally developed for other popu-
lations, have high test-retest reliability in people with MS
(ABC 0.92, DHI 0.90) [22]. They also have fair concurrent
validity with each other and identify individuals who fall
better than a number of clinician-administered measures
including the BBS, the TUG test, the Ambulation Index, and
the Dynamic Gait Index [10]. Both the ABC and DHI have
also been found to be responsive to the change in trials of
rehabilitation interventions. Ylva Nilsag˚ ard, PT, Ph.D., from
Orebro University in Sweden, focused on using self-reported
measures to identify people with MS at increased risk for
falling and to determine predictors of falls in people with
MS. In a recent study by Dr. Nilsag˚ ard, close to 2/3 of MS
subjects recorded falls prospectively in a 3-month period
[23]. Factors associated with falls were imbalance, weakness,
fatigue, and environmental or task-speciﬁc factors including
being bumped by others, walking in crowds, on ramps, or
while carrying objects.
Self-administered measures of gait and balance in MS
provide insight into patients’ perspectives about their abili-
ties, are inexpensive to administer, most have minimal ﬂoor
and ceiling eﬀects, and identify who is at increased risk
for falls. However, because these measures do not provide
information on neuroanatomical, biomechanical, environ-
mental, or personal factors contributing to gait and balance
impairment in MS, or shed light on the impact of activity
limitations on an individual’s participation or quality of
life, they give limited guidance for intervention [24]. The
speakers recommended using these measures, in addition to
clinician-administered measures, for screening people with
MS for gait dysfunction, imbalance, and fall risk, and as
outcome measures in trials of interventions expected to have
a positive impact on mobility and quality of life.
4. InstrumentedMeasures
Whenpreciseinformationaboutgaitandbalanceareneeded,
instrumented measures are recommended. As related by Fay
Horak, PT, Ph.D., and Jessie Huisinga, Ph.D. from OHSU,
and Robert Motl, Ph.D., from the University of Illinois at
Urbana-Champaign, until recently, sophisticated and bulky
equipment installed in specialized motion-analysis laborato-
ries was needed to obtain precise, accurate quantitative gait
and balance data. Now, however, wearable sensors housing
triaxial accelerometers, gyroscopes, and magnetometers are
increasingly used in research settings, and a variety of
pedometers and accelerometers are readily available for
clinical and home use. These portable devices are also less
expensive, require less technical expertise than laboratory-
basedinstruments,andcanbeusedtoassessgaitandbalance
in various environments including at home and otherMultiple Sclerosis International 3
“real world” situations. Wearable sensors may have the sen-
sitivity to detect MS-related disability when the clinician
cannot [25] and may provide more precise long-term moni-
toringofdisabilityprogression,thusreducingthesamplesize
and trial duration required to determine treatment eﬃcacy.
Despite their great potential, currently, integration of
novel instrumented measures of gait and balance into MS
clinical practice and research is limited by lack of test pro-
tocol and device standardization. We also need to know if
these devices are sensitive to changes associated with MS
progression and treatment. However, their validation is
challenging because it is not clear what measures should be
used as a gold standard for comparison. In addition, we do
not know how acceptable, feasible, and aﬀordable these new
instrumentedmeasureswillbeforclinicalpracticeandlarge-
scale clinical trials.
5. Relationships between Novel MRI
Measures andInstrumentedMeasuresof
GaitImpairment
The ﬁnal speaker of the day, Kathleen Zackowski, Ph.D.,
OTR, from Kennedy Krieger Institute and Johns Hopkins
University, discussed current research on the relationships
b e t w e e nc o n v e n t i o n a la sw e l la sn o v e lM R Im e a s u r e ss u c ha s
magnetization transfer (MT) and diﬀusion tensor imaging
(DTI) with instrumented measures of speciﬁc impairments
as well as balance and gait changes. She noted that the use
of MT and DTI in MS has been growing. These methods
allow for a noninvasive evaluation of white matter that
is especially useful in diseases where myelin and axonal
integrity are disrupted [26–30]. MT indirectly assesses the
status of water protons associated with macromolecular
structures in tissues such as myelin and is especially useful
for studying white matter integrity because white matter
h a ss u c hah i g hm y e l i nc o n t e n t[ 31]. However, MT can
sensitively quantify white and gray matter abnormalities in
both brain and spinal cord [32–34]. DTI-derived indices are
sensitive to macroscopic and microscopic tissue disruption
and appear to have higher speciﬁcity than conventional
imaging for areas aﬀected by MS pathology [35]. Using
tractography, DTI can deﬁne the approximate anatomy
of individual white matter tracts within the brain and
spinal cord [36]. DTI can identify abnormal values of MRI
indices in speciﬁc white matter tracts that may underlie
clinical disability in MS, and the integration of information
derived from other imaging sequences, such as MT, can
increase pathologic speciﬁcity [34, 37]. DTI abnormalities
in the corticospinal tract have been shown to correlate with
weakness in MS [38]. These advanced MRI measures may
be able to detect and quantify subtle subclinical changes
in function impacted by neurorehabilitation and link these
with disease pathology. For example, Zackowski et al. [34]
demonstrated relationships between instrumented walking
velocity measures and DTI and MT indices of the spinal
cord in MS. New MRI techniques together with novel
instrumented measures of gait and balance may also allow
us to deﬁne the anatomic substrates of disability and to
design speciﬁc innovative rehabilitation strategies for people
with MS based on the relationships between structure and
function.However,larger,morecomprehensivestudiesusing
a combination of instrumented measures of walking and
clinical rating scales, along with more speciﬁc MRI indices,
such as those from DTI and MT, are needed.
6. Discussion
The symposium concluded with a panel discussion by all of
the speakers. The panelists concurred that
(1) measures of gait and balance dysfunction should be
used throughout the course of MS;
(2) currently, available simple clinician and self-admin-
istered measures are recommended for screening for
imbalance, gait dysfunction, and fall risk;
(3) self-administered measures are important for captur-
ing the patients’ perspective of their abilities and the
eﬀectiveness of interventions;
(4) more complex clinician-administered measures and
instrumented measures are recommended to guide
the selection and development of tailored interven-
tions for walking and balance problems in people
withMSandforprecisemonitoringofchangeinclin-
ical trials;
(5) remaining critical research needs are to identify and
standardize the most scientiﬁcally valid and practi-
cally useful measures to capture the continuum of
gait and balance deﬁcits in MS and to understand the
relationships between these measures.
Abstracts of posters of primary research presented at this
symposium were published in Winter 2011 International
Journal of MS Care. The Second International Gait and Bal-
ance Symposium in MS is scheduled to be held in Portland,
Oregon on October 19th and 20th 2012 and will focus on
interventions for gait impairment, imbalance, and falls in
people with MS.
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